2-Heteroarylidene-1-indanone derivatives as inhibitors of monoamine oxidase

被引:28
作者
Nel, Magdalena S. [1 ,2 ]
Petzer, Anel [1 ,2 ]
Petzer, Jacobus P. [1 ,2 ]
Legoabe, Lesetja J. [2 ]
机构
[1] North West Univ, Sch Pharm, Pharmaceut Chem, Private Bag X6001, ZA-2520 Potchefstroom, South Africa
[2] North West Univ, Ctr Excellence Pharmaceut Sci, Private Bag X6001, ZA-2520 Potchefstroom, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Indanone; Monoamine oxidase; MAO; Inhibition; Chalcone; SAR; Heterocyclic; REVERSIBLE INHIBITORS; B INHIBITION;
D O I
10.1016/j.bioorg.2016.09.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the present study a series of fifteen 2-heteroarylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. These compounds are structurally related to series of heterocyclic chalcone derivatives which have previously been shown to act as MAO-B specific inhibitors. The results document that the 2-heteroarylidene-1-indanones are in vitro inhibitors of MAO-B, displaying IC50 values of 0.0044-1.53 mu M. Although with lower potencies, the derivatives also inhibit the MAO-A isoform with IC50 values as low as 0.061 mu M. An analysis of the structure-activity relationships for MAO-B inhibition indicates that substitution with the methoxy group on the A-ring leads to a significant enhancement in MAO-B inhibition compared to the unsubstituted homologues while the effect of the heteroaromatic substituent on activity, in decreasing order is: 5-bromo-2-furan > 5-methyl-2-furan > 2-pyridine approximate to 2-thiophene > cyclohexyl > 3-pyridine approximate to 2-furan. It may therefore be concluded that 2-heteroarylidene-1-indanone derivatives are promising leads for the design of MAO inhibitors for the treatment of Parkinson's disease and possibly other neurodegenerative disorders. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:20 / 28
页数:9
相关论文
共 28 条
[1]  
[Anonymous], 2005, ACC DISC STUD 3 1
[2]   Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs [J].
Binda, Claudia ;
Wang, Jin ;
Pisani, Leonardo ;
Caccia, Carla ;
Carotti, Angelo ;
Salvati, Patricia ;
Edmondson, Dale E. ;
Mattevi, Andrea .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (23) :5848-5852
[3]   Moclobemide: Therapeutic use and clinical studies [J].
Bonnet, U .
CNS DRUG REVIEWS, 2003, 9 (01) :97-140
[4]   New Frontiers in Selective Human MAO-B Inhibitors [J].
Carradori, Simone ;
Silvestri, Romano .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) :6717-6732
[5]   Novel monoamine oxidase inhibitors: a patent review (2012-2014) [J].
Carradori, Simone ;
Petzer, Jacobus P. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2015, 25 (01) :91-110
[6]   Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors [J].
Chimenti, Franco ;
Fioravanti, Rossella ;
Bolasco, Adriana ;
Chimenti, Paola ;
Secci, Daniela ;
Rossi, Francesca ;
Yanez, Matilde ;
Orallo, Francisco ;
Ortuso, Francesco ;
Alcaro, Stefano .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (09) :2818-2824
[7]  
Da Prada M, 1988, J Neural Transm Suppl, V26, P31
[8]  
DeLano WL., 2002, PYMOL MOL GRAPHICS S
[9]   Monoamine oxidase-B inhibition in the treatment of Parkinson's disease [J].
Fernandez, Hubert H. ;
Chen, Jack J. .
PHARMACOTHERAPY, 2007, 27 (12) :174S-185S
[10]  
Finberg JPM, 1998, J NEURAL TRANSM-SUPP, P279